TAGRISSO
Be bullish, just manage risks & desire; 5 midcap stocks for long term investors
In a bullish market many things change and one of them is the relationship between opportunity and challenges. Given the way markets are panning out, yes there are opportunities to make returns in a short term. But the challenge is finding the right stock which not only delivers a return in the short term but is also worth holding in the portfolio for the long term. This challenge emerges from the fact that valuations are at a higher level and a small negative news can damage prices much more and time wise correction can lead to returns turning much lower. So, there are two things which need to be managed, first avoid the risk of getting into wrong stocks and second is manage the desire of making all the returns in the short term.
Indian companies have made a comeback. Will MNCs be able to do it ? 7 MNC pharma stocks with upside potential of up to 21%
While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having a MNC stock in your portfolio is an assurance of growth and return no longer holds true. There was a time when having MNC stock, irrespective of the sector it was from, was a must have in one's portfolio. The reason: liberal at giving bonuses, dividend payments were good and given the fact some of them actually owned the best of the brands which had seen a secular growth due to which they were also able to deliver decent returns to shareholders. But after the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the street. In the last few years, a number of pharma companies have been putting their house in order, either due to global merger and selling a part of Indian business to focus more on core products.
AstraZeneca bets on licencing deals, public-private partnerships for India growth
British-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, renal, and metabolic diseases, respiratory and immunology, and rare diseases. The company aims to expand access to its therapies through public-private partnerships, licensing deals, and tiered pricing. AstraZeneca's India business returned to growth in FY23 after a period of plateauing sales, driven by innovative molecules.
Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%
In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of these restructuring are being done as part of the global readjustment being made at the parent companies level. The bigger question is whether after this restructuring will the MNC pharma stocks, which have been underperforming for quite some time, be able to make a comeback on the street or not. This answer to this question would depend on multiple factors. Right from the use of the sale proceeds to whether post restructuring focus would be on a 100 percent subsidiary or not. In both positive and negative cases, these stocks probably should be on watchlist as news flow around them increases in coming quarters. We take a look at 7 MNC pharma companies.
AstraZeneca targets 2024 growth but mixed views hit shares
In almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker's pipeline, which includes 13 blockbuster medicines, meaning those that generate more than $1 billion in annual sales.
For calibrating and diversifying risks? 6 midcap stocks from different sectors with the right financial matrix
As the Dalal street continues to be in party mode, staying bullish would appear to be the most logical thing at this point of time. Why fight against a trend, while staying bullish, just add an element of caution. When we use the word caution, we mean stay with quality and especially if one is increasing exposure at this point of time. There is enough evidence to show that owning quality stocks pays both in bullish and bearish markets conditions. In a bullish market, they tend to rise faster and when a bearish phase comes, they do lose weight like others but less as compared and have shown tendency to recover fast post a bearish phase. so stay bullish but be selective.
- Go To Page 1
Miracle pill can keep lung cancer at bay: Report
The treatment developed by the pharmaceutical group AstraZeneca is called osimertinib and is marketed under the name Tagrisso.
AstraZeneca starts to make modest profit from Covid-19 vaccine
The Anglo-Swedish company's third-quarter results showed the vaccine contributed one cent to core earnings per share of $1.08, a rise of 14%. Total product sales jumped 49% to $9.74 billion, as its vaccine sales topped $1 billion.
AstraZeneca working on vaccine to prevent and cure Covid: MD Gagandeep Singh
Anglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long-acting antibody combination (LAAB) for the potential prevention and treatment of Covid-19, pharma company's India managing director Gagandeep Singh told ET.
Stocks in the news: HDFC, Ruchi Soya, GIC, Ircon and IRCTC
Ircon, Swan Energy, Dish TV India, BF Utilities, Prime Focus, Anant Raj, Andhra Sugars and Sadbhav Engineering will announce their March quarter results today.
AstraZeneca Pharma India moves Delhi High Court against NPPA demand notice
The notice of demand alleges that the company has overcharged about Rs 157.38 crore during the period from March 8, 2019 to January 31, 2021 in respect of Tagrisso (Osimertinib) 80 mg tablets.
AstraZeneca says on track to deliver on Covid shots as sales hit $275 mn
When including production and distribution from partners such as the Serum Institute of India, more than 300 million doses have been supplied globally.
AstraZeneca approaches Gilead about potential merger
AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger.
Load More
